FrancophonIA/ELRC3.0 huggingface dataset:
English: Each orodispersible tablet contains rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine.
Maltese: Kull kapsula iebsa fiha rivastigmine hydrogen tartrate ekwivalenti għal 6 mg rivastigmine.
English: 28 hard capsules: EU/1/09/525/014
Maltese: EU/1/09/525/014
English: 60 hard capsules: EU/1/09/525/023
Maltese: EU/1/09/525/023
English: The mean actual daily dose for responders in the 6-12 mg group, corresponding to this definition, was 9.3 mg.
Maltese: Id-doża medja attwali ta' kuljum għal dawk li wrew rispons filgrupp ta' minn 6 - 12-il mg, li tikkorispondi ma' din id-definizzjoni, hija ta' 9.3 mg.
English: Uncommon Uncommon Very rare
Maltese: Mhux komuni Mhux komuni Rari ħafna
English: Each orodispersible tablet contains rivastigmine hydrogen tartrate equivalent to 1.5 mg rivastigmine.
Maltese: Kull pillola li tinħall fil-ħalq fiha rivastigmine hydrogen tartrate ekwivalenti għal 1.5 mg rivastigmine.
English: 28 hard capsules: EU/1/09/525/020
Maltese: EU/1/09/525/020
English: The following adverse reactions, listed below in Table 1, have been accumulated in patients with Alzheimer's dementia treated with rivastigmine.
Maltese: Ir-reazzjonijiet avversi li ġejjin, elenkati hawn taħt f'Tabella 1, kienu miġbura minn pazjenti kkurati b'rivastigmine għal dimenzja t'Alzheimer.
English: Mean baseline ± SD Mean change at 24 weeks ± SD
Maltese: Medja tal-linja bażi ± SD Bidla medja f'24 ġimgħa ± SD
English: Musculoskeletal stiffness Rigors
Maltese: Infezzjoni fis-sistema tal-awrina
English: Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones.
Maltese: L-impedituri ta cholinesterase għandhom jiġu preskritti b'attenzjoni lil pazjenti bi storja ta' ażma jew mard pulmonarju ostruttiv.
English: Nimvastid 6 mg hard capsules, which contain a white to almost white powder, have a brownish red cap and orange body.
Maltese: Nimvastid 6 mg kapsuli ibsin, li fihom trab bajdani għal kważi bajdani, għandhom ras ħamranija filkannella u korp oranġjo.
English: 60 hard capsules: EU/1/09/525/011
Maltese: EU/1/09/525/011
English: Cmax and AUC of rivastigmine were more than twice as high in subjects with moderate renal impairment compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in subjects with severe renal impairment.
Maltese: Is-Cmax u l-AUC ta' rivastigmine kienu aktar minn darbtejn ogħla f'pazjenti li kellhom indeboliment tal-kliewi moderat meta mqabbla ma' individwi b'saħħithom; madankollu ma' kien hemm l-ebda tibdiliet fis-Cmax u AUC ta' rivastigmine f'individwi b'indeboliment tal-kliewi sever.
English: By blocking these enzymes, Nimvastid allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's disease and dementia associated with Parkinson's disease.
Maltese: Il-kura għandha tinbeda u tkun segwita minn tabib li għandu esperjenza fid-dijanjosi u l-kura ta' dimenzja ta' Alzheimer jew dimenzja assoċjata mal-marda ta' Parkinson.
English: If you are pregnant, the benefits of using Nimvastid must be assessed against the possible effects on your unborn child. Nimvastid should not be used during pregnancy unless clearly necessary.
Maltese: Jekk ħriġt tqila, il-benefiċċji ta' Nimvastid għandhom jiġu evalwati kontra l-effetti li jista' jkun hemm fuq it-tarbija li għadha ma twelditx.
English: Hyperhydrosis
Maltese: Iperidrożi
English: • Fits (seizures)
Maltese: TWISSIJA(IET) SPEĊJALI
English: Dose titration: Adverse reactions (e.g. hypertension and hallucinations in patients with Alzheimer's dementia and worsening of extrapyramidal symptoms, in particular tremor, in patients with dementia associated with Parkinson's disease) have been observed shortly after dose increase.
Maltese: Ġew osservati reazzjonijiet avversi (eż. pressjoni għolja u alluċinazzjonijiet f'pazjenti b'dimenzja ta' Alzheimer u sintomi ekstrapiramidali li jmorru għall-agħar, l-aktar rogħda, f'pazjenti b'dimenzja assoċjata mal-marda ta' Parkinson) ftit wara li ġiet miżjuda d-doża.
English: Pre-defined adverse events that may reflect worsening of parkinsonian symptoms in patients with dementia associated with Parkinson's disease
Maltese: Każijiet avversi ddefiniti minn qabel li jistgħu jirriflettu aggravament tas-sintomi tal-marda ta' Parkinson f'pazjenti b'dimenzja assoċjata malmarda ta' Parkinson
English: When normalised to body surface area, the exposure to rivastigmine and its metabolites was approximately equivalent to the maximum recommended human dose of 12 mg/day; however, when compared to the maximum human dose, a multiple of approximately 6-fold was achieved in animals.
Maltese: Meta ġew imqabbla mal-erja tas-superfiċje tal-ġisem, lespożizzjoni għal rivastigmine u l-metaboliti tiegħu kienet bejn wieħed u ieħor ekwivalenti għad-doża massima rrakkomandata fil-bniedem ta' 12 mg/jum; madankollu, meta mqabbla mad-doża massima fil-bniedem, livelli ta' bejn wieħed u ieħor 6 darbiet aktar kienu milħuqa fl-annimali.
English: A mild eye/mucosal irritation potential of rivastigmine was identified in a rabbit study.
Maltese: Kien identifikat potenzjal ta' irritazzjoni ħafifa fl-għajn/fil-mukoża minn rivastigmine waqt studju bilfniek.
English: White to almost white powder in a capsule with a brownish red cap and orange body.
Maltese: Trab abjad għal kważi abjad f'kapsula b'ras oranġjo u korp oranġjo.
English: Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristic, Section 4.2.)
Maltese: Prodott mediċinali jingħata b'riċetta ristretta tat-tabib (ara Anness I: Sommarju tal-Karatteristiċi tal-Prodott, sezzjoni 4.2).
English: According to its metabolism, metabolic interactions with other medicinal products appear unlikely, although rivastigmine may inhibit the butyrylcholinesterase mediated metabolism of other substances.
Maltese: Minħabba l-metaboliżmu tiegħu, mhux mistenni li jkun hemm interazzjonijiet metaboliċi ma' prodotti mediċinali oħra, għalkemm rivastigmine jista' jinibixxi l-metaboliżmu ta' sustanzi oħra li jsir permezz ta' butrylcholinesterase.
English: Decreased appetite Dehydration
Maltese: Nuqqas ta' aptit Deidrazzjoni
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Maltese: KRKA Magyarország Kereskedelmi
English: EMA/20928/2016 EMEA/H/C/004104
Maltese: EMEA/H/C/004104
English: Eptifibatide Accord is a ‘generic medicine'.
Maltese: Eptifibatide Accord huwa 'mediċina ġenerika'.
English: The full EPAR and risk management plan summary for Eptifibatide Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: L-EPAR sħiħ u s-sommarju tal-pjan tal-ġestjoni tar-riskju għal Eptifibatide Accord jinstabu fis-sit elettroniku tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The medicine contains the active substance eptifibatide.
Maltese: Il-mediċina fiha s-sustanza attiva eptifibatide.
English: It is available as solutions for infusion (drip) and injection into a vein.
Maltese: Jiġi bħala soluzzjonijiet għall-infużjoni (dripp) u injezzjoni ġol-vina.
English: This is followed by a continuous infusion of 2.0 microgram/kg per minute which is continued for up to 72 hours, until the start of heart surgery, or until discharge from the hospital, whichever occurs first.
Maltese: Din hija segwita minn infużjoni kontinwa ta' 2.0 mikrogrammi/kg fil-minuta li tibqa' sejra sa 72 siegħa, sakemm jibda l-intervent kirurġiku talqalb, jew sakemm il-pazjent jintbagħat mill-isptar, skont liema minnhom isseħħ l-ewwel.
English: This is a summary of the European public assessment report (EPAR) for Eptifibatide Accord.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Eptifibatide Accord.
English: Other information about Eptifibatide Accord
Maltese: Informazzjoni oħra dwar Eptifibatide Accord
English: If the patient undergoes a percutaneous coronary intervention (PCI or angioplasty, a surgical procedure that is used to unblock narrowed coronary arteries), infusion of Eptifibatide Accord can be continued for up to 24 hours after the procedure, with a maximum treatment duration of 96 hours.
Maltese: Jekk ilpazjent isirlu intervent perkutanju koronarju (PCI jew anġjoplastika, proċedura kirurġika li ssir biex tiżblokka arterji koronarji dojoq), l-infużjonijiet ta' Eptifibatide Accord jistgħu jitkomplew sa mhux iktar minn 24 siegħa wara l-intervent kirurġiku, sa durata massima tal-kura ta' 96 siegħa.
English: Eptifibatide Accord is given with aspirin and unfractionated heparin (other medicines that prevent blood clots).
Maltese: Eptifibatide Accord jingħata mal-aspirina u l-eparina mhux frazzjonata (mediċini oħra li jipprevjenu emboli).
English: • patients who have already had a non-Q-wave myocardial infarction (a type of heart attack), with chest pain in the last 24 hours and with abnormalities on the electrocardiogram (ECG) or signs of heart problems in the blood.
Maltese: • pazjenti li diġà kellhom infart mijokardijaku mhux tal-mewġa Q (tip ta' attakk tal-qalb), b'uġigħ f'sidirhom fl-aħħar 24 siegħa u b'anormalitajiet fl-elettrokardjogramma (ECG) jew sinjali ta' problemi fil-qalb fid-demm.
English: The company provided data from the published literature on eptifibatide.
Maltese: Il-kumpanija pprovdiet dejta minn dokumentazzjoni ppubblikata dwar eptifibatide.
English: Eptifibatide Accord is an inhibitor of platelet aggregation.
Maltese: Eptifibatide Accord huwa inibitur tal-aggregazzjoni tal-plejtlits.
English: This includes patients who are having percutaneous transluminal coronary angiography (PTCA, a type of surgery to clear the arteries supplying the heart).
Maltese: Dan jinkludi pazjenti li għandhom anġjoplastika koronarja transluminali perkutanja (PTCA, tip ta' kirurġija biex tnaddaf l-arterji li jissupplixxu l-qalb).
English: The active substance in Eptifibatide Accord, eptifibatide, stops the platelets aggregating by blocking a protein called glycoprotein IIb/III on their surface that helps make them sticky.
Maltese: Is-sustanza attiva f'Eptifibatide Accord, eptifibatide, twaqqaf ilplejtlits milli jaggregaw billi timblokka proteina msejħa glikoproteina IIb/III fuq il-wiċċ tagħhom li tgħin sabiex jeħlu.
English: This means that Eptifibatide Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Integrilin.
Maltese: Dan ifisser li Eptifibatide Accord huwa simili għall‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Europea (UE) li jisimha Integrilin.
English: • patients who have unstable angina (chest pain caused by poor blood flow to the heart, that may occur at rest or without an obvious trigger);
Maltese: • pazjenti li għandhom anġina instabbli (uġigħ fis-sider ikkawżat minn fluss baxx tad-demm għallqalb, li jista' jseħħ waqt il-mistrieħ jew mingħajr kawża ovvja);
English: Eptifibatide Accord eptifibatide
Maltese: Kif jintuża Eptifibatide Accord?
English: No additional studies were needed as Eptifibatide Accord is a generic medicine that is given by injection and infusion into a vein and contains the same active substance as the reference medicine, Integrilin.
Maltese: L-ebda studju addizzjonali ma kien meħtieġ minħabba li Eptifibatide Accord huwa mediċina ġenerika li tingħata b'infużjoni ġol-vina u fiha l-istess sustanza attiva bħall-mediċina ta' referenza, Integrilin.
English: The Committee recommended that Eptifibatide Accord be approved for use in the EU.
Maltese: Il-Kumitat irrakkomanda li Eptifibatide Accord ikun approvat għall-użu fl-UE.
English: Why is Eptifibatide Accord approved?
Maltese: Għaliex ġie approvat Eptifibatide Accord?
English: What are the benefits and risks of Eptifibatide Accord?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Eptifibatide Accord?
English: EPAR summary for the public
Maltese: Sommarju tal-EPAR għall-pubbliku eptifibatide
English: How is Eptifibatide Accord used?
Maltese: Kif jaħdem Eptifibatide Accord?
English: How has Eptifibatide Accord been studied?
Maltese: Kif ġie studjat Eptifibatide Accord?
English: A risk management plan has been developed to ensure that Eptifibatide Accord is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Eptifibatide Accord jintuża bl-aktar mod sigur possibbli.
English: Because Eptifibatide Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Eptifibatide Accord huwa mediċina ġenerika, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: Therefore, the CHMP's view was that, as for Integrilin, the benefit outweighs the identified risk.
Maltese: Għaldaqstant, il-fehma tas-CHMP kienet li, bħal fil-każ ta' Integrilin, il-benefiċċju huwa akbar mir-riskju identifikat.
English: Camprodón, s/n°, Finca La Riba, Vall de Bianya, 17813 Girona Spain
Maltese: Camprodón, s/n°, Finca La Riba, Vall de Bianya, 17813 Girona
English: [Not applicable.]
Maltese: [Mhux applikabbli.]
English: Antagonism may be observed with nitrofurantoin.
Maltese: Jista' jkun hemm antagoniżmu ma nitrofurantoin.
English: ATC vet code: QJ01MA94
Maltese: QJ01MA94
English: Sodium starch glycollate Microcrystalline cellulose Magnesium stearate Colloidal silicon dioxide Sodium lauryl sulphate
Maltese: Microcrystalline cellulose Magnesium stearate Colloidal silicon dioxide Sodium lauryl sulphate Lactose
English: Escherichia coli Klebsiella spp.
Maltese: Eschericia coli Klebsiella spp.
English: 3 OJ No. L 290 of 5.12.95
Maltese: 3 OJ Nru. L 290 ta' 5.12.95
English: CARTON OF 10 TABLETS / 20 TABLETS / 100 TABLETS
Maltese: KARTUNA TA' 10 PILLOLI / 20 PILLOLA / 100 PILLOLA
English: Pharmacotherapeutic group: general anti-infectives for systemic use; antibacterials for systemic use, quinolone antibacterials.
Maltese: Grupp Farmako-terapewtiku: sustanza anti-infettiva ġenerali għal użu sistemiku, sustanza antibatterika għal użu sistemiku, antibatteriku tal-klassi Quinolone
English: A half-life time of 5.8 hours has been observed.
Maltese: Kien osservat half-life ta' 5.8 siegħat.
English: Tissue to plasma ratios range from 0.6 (abdominal fat), 2.4 (lung), 4.5 (muscle) to 14.1 (liver).
Maltese: Il-proporzjon ta' tessut għal plażma kien ivarja minn 0.6 (xaħam taż-żaqq), 2.4 (pulmun), 4.5 (muskoli) għal 14.1 (fwied).
English: Superficial pyoderma may require treatment for up to a maximum of 21 days.
Maltese: Pijoderma superfiċjali jista jkollha bżonn trattament sa massimu ta' 21 ġurnata.
English: A fraction of difloxacin (i.e. 7 - 18%) is eliminated via the urine.
Maltese: Parti minn Difloxacin (7 - 18%) kien imneħħi mill-urina.
English: Tissue to plasma ratios range from 2.5 (abdominal fat), 3.7 (muscle), 4.8 (lung) to 36.5 (liver).
Maltese: Il-proporzjon ta' tessut għal plażma kien ivarja minn 2.5 (xaħam taż-żaqq), 3.7 (muskoli), 4.8 (pulmun) għal 36.5 (fwied).
English: 1 OJ No. L 172 of 02.07.02
Maltese: 1 OJ Nru. L 172 ta' 02.07.02
English: Dicural 15 mg coated tablets for dogs Dicural 50 mg coated tablets for dogs Dicural 100 mg coated tablets for dogs Dicural 150 mg coated tablets for dogs
Maltese: Dicural 15 mg pilloli miksija għal klieb Dicural 50 mg pilloli miksija għal klieb Dicural 100 mg pilloli miksija għal klieb Dicural 150 mg pilloli miksija għal klieb
English: 2 OJ No. L 172 of 02.07.02
Maltese: 2 OJ Nru. L 172 ta' 02.07.02
English: Whenever possible, fluoroquinolones should only be used based on susceptibility testing.
Maltese: Meta possibli, fluoroquinolones għandhom jintużaw biss wara testijiet ta' suxxettibilità.
English: Dogs: treatment of:
Maltese: Klieb: trattament ta'
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:
Maltese: U KWANTITATTIVA Sustanzi Attiva:
English: Pharmacologically active substance
Maltese: Sustanzi farmakoloġikament attivai
English: D. STATEMENT OF THE MRLs which are accepted in accordance with Council Regulation (EEC) No 2377/90 and in accordance with Article 31 (3b) of Council Regulation (EEC) No 2309/93 of 22 July 1993, as amended.
Maltese: DIKJARAZZJONI TA' L-MRLs li huma aċċettati b'mod konformi mar-Regolament tal-Kunsill (KEE) Nru 2377/90 u b'mod konformi ma' l-Artikolu 31 (3b) tar-Regolament tal-Kunsill (KEE) Nru 2309/93 tat-22 ta' Lulju 1993, kif emendati.
English: In general the pruritis disappears within a few minutes and the local swelling within a few days.
Maltese: Ġeneralment it-tnixxija titlaq fi ftit minuti u n-nefħa lokali wara ftit ġranet.
English: Treatment of:
Maltese: Trattament ta':
English: Cardboard boxes of 1, 2 or 10 blisters.
Maltese: Kaxxi tal-kartun li fihom 1, 2 jew 10 strixxi.
English: Difloxacin (as hydrochloride)
Maltese: Difloxacin (bħala hydrochloride)
English: Difloxacin can be bactericidal against many Gram-negative micro-organisms and a selection of Gram-positive microorganisms.
Maltese: Difloxacin joqtol ħafna mikro-organiżmi Gram negative u uħud Gram positive.
English: 4.10 Overdose (symptoms, emergency procedures, antidotes)
Maltese: 4.10 Doża eċċessiva (sintomi, proċeduri ta' emerġenza, antidoti) jekk ikun hemm bżonn
English: After subcutaneous administration of difloxacin peak plasma levels of 1.4 -1.9 g/ml are achieved in 3.1 hours post dosing.
Maltese: Wara amministrazzjoni taħt il-ġilda, Difloxacin laħaq l-ogħla livelli fil-plażma ta' 1.4 - 1.9 mikrogrammi /ml fi 3.1 siegħat wara l-amministrazzjoni.
English: Difloxacin is an aryl-fluoroquinolone with a broad spectrum of antimicrobial activity.
Maltese: Difloxacin huwa aryl-fluoroquinolone bi spettru wiesa ta' attività antibatterika.
English: Escherichia coli Staphylococcus intermedius
Maltese: Mycoplasma spp Eschericia coli Staphylococcus intermedius
English: Edetic acid Potassium hydroxide Propylene glycol Benzyl alcohol Purified water
Maltese: Edetic acid Potassium hydroxide Propylene glycol
English: 7 OJ No. L 143 of 27.06.95
Maltese: 7 OJ Nru. L 143 ta' 27.06.95
English: 6 OJ No. L 143 of 27.06.95
Maltese: 6 OJ Nru. L 143 ta' 27.06.95
English: • Superficial pyoderma caused by Staphylococcus intermedius.
Maltese: • Infezzjoni superfiċjali (pijoderma) ikkawżata minn Staphylococcus intermedius.
English: Strains of Escherichia coli, Pasteurella multocida, Mycoplasma gallisepticum isolated from broilers and turkeys have been shown to be sensitive to difloxacin.
Maltese: Ġie muri li razez ta' Eschericia coli, Pasteurella multocida, Mycoplasma gallisepticum, iżolati minn flieles tas-simna jew dundjani kienu kollha sensittivi għal Difloxacin.
English: • Acute uncomplicated urinary tract infections caused by Escherichia coli or Staphylococcus spp.
Maltese: • Infezzjonijiet akuti u bla kumplikazzjonijiet fis-sistema tal-urina, ikkawżati minn Eschericia coli jew Staphylococcus spp.
English: [MA Number recommended, but not required on the immediate label] EU/2/97/003/016
Maltese: [In-Numru ta' l-Awtorizzazzjoni tal-Kummerċ mhux meħtieġ fuq it-tikketta li tmiss mal-prodott] EU/2/97/003/016
English: Micronised brewer's yeast
Maltese: Sodium croscarmellose Micronised brewer's yeast Aromatic liver flavour
English: 4.11 Withdrawal period
Maltese: 4.11 Perjodu ta' Tiżmin
English: Nitrofurantoin may impair quinolone efficacy if used concurrently in the treatment of urinary tract infections.
Maltese: Nitrofurantoin jista' jnaqqas l-effikaċja ta' quinolones jekk jintużaw flimkien waqt infezzjonijiet talpassaġġ tal-urina
English: MARKETING AUTHORISATION NUMBER(S) EU/2/97/003/001 - 1 x 250 ml EU/2/97/003/002 - 1 x 1000 ml EU/2/97/003/003 - 6 x 1000 ml
Maltese: NUMRU TA' L-AWTORIZAZZJONI TAL-KUMMERĊ EU/2/97/003/001 - 1 x 250 ml
English: 5.2 Pharmacokinetic properties
Maltese: 5.1 Kwalitajiet Farmakodinamiċi
English: It is very well distributed in the body (Vd = 9.9 l/kg) and has a plasma elimination half-life of approximately 7 hours.
Maltese: Difloxacin jitqassam tajjeb ħafna fil-ġisem (Vd = 9.9 l/kg) u għandu elimination half-life fil-plażma ta' madwar 7 siegħat.
English: After subcutaneous administration the bioavailability is 88% and the volume of distribution is 2.5 l/kg.
Maltese: Wara titqiba taħt il-ġilda, il-biodisponibiltà hija ta' 88% u l-volum ta' distribuzzjoni hu ta' 2.5 l/kg.
English: The elimination half-life averaged 9.3 hours.
Maltese: Il-medja tal-half-life tal-eliminazzjoni kienet 9.3 siegħat.
English: The majority of difloxacin (i.e. 68 - 82%) is excreted via the faeces.
Maltese: Il-parti l-kbira ta' Difloxacin (68 - 82%) kien imneħħi filħmieġ.
English: Difloxacin Bovine2
Maltese: Difloxacin Tjur1
English: Lactose
Maltese: Klieb
English: Potassium Hydroxide4 Propylene glycol5
Maltese: Propylene glycol5
English: The main metabolites are hydrolysable conjugates of difloxacin, the other metabolites are proportionally minor ones.
Maltese: Il-metaboliti ewlenin huma konjugati idrolisabbli ta'Difloxacin, il-metaboliti l-oħra huma proporzjonalment ftit.
English: Medicated water must be freshly prepared daily.
Maltese: Ilma medikat għandu jkun ippreparat frisk kuljum.
English: MARKETING AUTHORISATION NUMBER(S) [Recommended, but not required on the immediate label] EU/2/97/003/017 - 100 ml
Maltese: NUMRU TA' L-AWTORIZAZZJONI GĦALL-KUMMERĊ [Rakkomandat, imma mhux meħtieġ fit-tikketta li tmiss mal-prodott] EU/2/97/003/017 - 100 ml
English: In turkeys: Dicural oral solution is also indicated for the treatment of infections caused by Pasteurella multocida.
Maltese: Dicural soluzzjoni orali huwa indikat ukoll għal trattament ta' infezzjonijiet ikkawżati minn Pasteurella multocida.
English: 10 OJ No L 143 of 26.06.95 11 OJ No. L 240 of 10.09.99
Maltese: 06.95 11 OJ Nru. L 240 ta' 10.
English: In chickens and turkeys: Dicural oral solution is indicated for treatment of chronic respiratory infections caused by sensitive strains of Escherichia coli and Mycoplasma gallisepticum.
Maltese: Dicural soluzzjoni orali huwa indikat għal trattament ta' infezzjonijiet kroniċi respiratorji kkawżati minn razez sensittivi ta' Eschericia coli u Mycoplasma gallisepticum.
English: total water consumption of the house at the previous day (litres)
Maltese: Konsum totali ta' ilma fil-maħżen il-ġurnata ta' qabel (litri)
English: The observed reactions were inappetence, emesis, diarrhoea, and anal irritation.
Maltese: Ir-reazzjonijiet osservati kienu inappettenza, rimettar, dijarea, u irritazzjoni fil-warrani.
English: Muscle Skin + fat Liver Kidney
Maltese: Muskolu Ġilda + xaħam Fwied Kliewi
English: Species
Maltese: VETERINARJU
English: Sodium croscarmellose
Maltese: Sodium starch glycollate
English: PACKAGE SIZE 1 x 250 ml 1 x 1000 ml 6 x 1000 ml
Maltese: 6 x 1000 ml
English: 5 OJ No. L 45 of 15.02.97
Maltese: 5 OJ Nru. L 45 ta' 15.
English: Coated tablets
Maltese: TAL-PRODOTT MEDIĊINALI
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products
Maltese: Fin-nuqqas ta' studji dwar kompattibilita, dan il-prodott mediċinali veterinarju ma jistax jintuża flimkien ma prodotti mediċinali veterinarji oħra.
English: Dicural oral solution is a yellowish clear aqueous solution and is supplied in plastic white bottles with a screw cap containing 250 or 1000 ml oral solution.
Maltese: Dicural soluzzjoni orali hija soluzzjoni trasparenti safranija u hija ppreżentata fi fliexken bojod talplastik b'tapp tal-kamin li jkun fihom 250 jew 1000 ml tas-soluzzjoni orali.
English: Chickens and turkeys - for treatment of chronic respiratory infections caused by sensitive strains of Escherichia coli and Mycoplasma gallisepticum.
Maltese: Fi flieles u dundjani, għal trattament ta' infezzjonijiet kroniċi respiratorji kkawżati minn strejns sensittivi ta' Eschericia coli u Mycoplasma gallisepticum.
English: The fluoroquinolones exert their antibacterial effect against both replicating and non-replicating micro-organisms.
Maltese: Il-fluoroquinolones għandhom effett antibatteriku kemm kontra mikro-organizmi li jirreplikaw kif ukoll dawk li ma jirreplikawx.
English: Marketing authorisation holder Pfizer Limited
Maltese: Pfizer Limited
English: Each tablet contains:
Maltese: Żmien ta' Tiżmin:
English: Dogs:
Maltese: Flieles:
English: Solution for injection: Pharmacologically active substance
Maltese: Sustanza(i) farmakoloġikament attiva(i)